MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525876 | Name: PDZ1i
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PDZ1i, also known as 113B7, is an inhibitor of MDA-9/Syntenin activity. PDZ1i radiosensitized GBM cells. PDZ1i inhibited crucial GBM signaling involving FAK and mutant EGFR, EGFRvIII, and abrogated gains in secreted proteases, MMP-2 and MMP-9, following radiation. In an in vivo glioma model, PDZ1i resulted in smaller, less invasive tumors and enhanced survival. When combined with radiation, survival gains exceeded radiotherapy alone.

Chemical Structure

PDZ1i
PDZ1i
CAS#2083618-79-3

Theoretical Analysis

MedKoo Cat#: 525876

Name: PDZ1i

CAS#: 2083618-79-3

Chemical Formula: C28H26N8O4

Exact Mass: 538.2077

Molecular Weight: 538.57

Elemental Analysis: C, 62.44; H, 4.87; N, 20.81; O, 11.88

Price and Availability

Size Price Availability Quantity
5mg USD 650.00 2 Weeks
10mg USD 1,150.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PDZ1i; 113B7;
IUPAC/Chemical Name
N-(2,5-Dimethyl-4-(3-(5-phenyl-1,3,4-oxadiazol-2-yl)propanamido)phenyl)-8-oxo-5,6,7,8-tetrahydro-4H-cyclopenta[d][1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide
InChi Key
DWWDFNUIUZQWOP-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H26N8O4/c1-15-14-21(30-25(38)24-32-28-31-19-10-6-9-18(19)27(39)36(28)35-24)16(2)13-20(15)29-22(37)11-12-23-33-34-26(40-23)17-7-4-3-5-8-17/h3-5,7-8,13-14H,6,9-12H2,1-2H3,(H,29,37)(H,30,38)(H,31,32,35)
SMILES Code
O=C(C1=NN(C(NC2=C3CCC2)=N1)C3=O)NC4=CC(C)=C(NC(CCC5=NN=C(C6=CC=CC=C6)O5)=O)C=C4C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
MDA-9/Syntenin (SDCBP) provides a direct target for therapy of aggressive cancers such as GBM, and defined small-molecule inhibitors such as PDZ1i hold promise to advance targeted brain cancer therapy.

Preparing Stock Solutions

The following data is based on the product molecular weight 538.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Pradhan AK, Modi J, Maji S, Kumar A, Bhoopathi P, Mannangatti P, Guo C, Afosah DK, Mochel MC, Mukhopadhyay ND, Kirkwood JM, Wang XY, Desai UR, Sarkar D, Emdad L, Das SK, Fisher PB. Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis. Mol Cancer Ther. 2023 Oct 2;22(10):1115-1127. doi: 10.1158/1535-7163.MCT-22-0653. PMID: 37721536. 2: Clark GC, Hampton JD, Koblinski JE, Quinn B, Mahmoodi S, Metcalf O, Guo C, Peterson E, Fisher PB, Farrell NP, Wang XY, Mikkelsen RB. Radiation induces ESCRT pathway dependent CD44v3+ extracellular vesicle production stimulating pro-tumor fibroblast activity in breast cancer. Front Oncol. 2022 Aug 29;12:913656. doi: 10.3389/fonc.2022.913656. PMID: 36106109; PMCID: PMC9465418. 3: Pradhan AK, Maji S, Bhoopathi P, Talukdar S, Mannangatti P, Guo C, Wang XY, Cartagena LC, Idowu M, Landry JW, Sarkar D, Emdad L, Cavenee WK, Das SK, Fisher PB. Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β. Proc Natl Acad Sci U S A. 2021 May 25;118(21):e2103180118. doi: 10.1073/pnas.2103180118. PMID: 34016751; PMCID: PMC8166168. 4: Bhoopathi P, Mannangatti P, Emdad L, Das SK, Fisher PB. The quest to develop an effective therapy for neuroblastoma. J Cell Physiol. 2021 Nov;236(11):7775-7791. doi: 10.1002/jcp.30384. Epub 2021 Apr 9. PMID: 33834508. 5: Bhoopathi P, Pradhan AK, Bacolod MD, Emdad L, Sarkar D, Das SK, Fisher PB. Regulation of neuroblastoma migration, invasion, and in vivo metastasis by genetic and pharmacological manipulation of MDA-9/Syntenin. Oncogene. 2019 Oct;38(41):6781-6793. doi: 10.1038/s41388-019-0920-5. Epub 2019 Aug 12. PMID: 31406249; PMCID: PMC6786950. 6: Das SK, Kegelman TP, Pradhan AK, Shen XN, Bhoopathi P, Talukdar S, Maji S, Sarkar D, Emdad L, Fisher PB. Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor. Mol Cancer Ther. 2019 Nov;18(11):1997-2007. doi: 10.1158/1535-7163.MCT-18-1019. Epub 2019 Jul 25. PMID: 31345950. 7: Kegelman TP, Wu B, Das SK, Talukdar S, Beckta JM, Hu B, Emdad L, Valerie K, Sarkar D, Furnari FB, Cavenee WK, Wei J, Purves A, De SK, Pellecchia M, Fisher PB. Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):370-375. doi: 10.1073/pnas.1616100114. Epub 2016 Dec 23. PMID: 28011764; PMCID: PMC5240699.

View History

Elfacos EHP

Elfacos EHP

ATV399

ATV399

RO5126946

RO5126946

Diprofene

Diprofene

FFENM

FFENM